lumacaftor

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Cystic FibrosisLung DiseaseHeart Failure With Reduced Ejection Fraction

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

1

lumacaftor

Vertex Pharmaceuticals

Phase 3

52

Onglyza

AstraZeneca

Preclinical

23

Calciferol

Alnylam Pharmaceuticals

Preclinical

14

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

35

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

26

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

27

Aztreonam Lysine

Gilead

Preclinical

58

Amitiza

SSucampo Pharma Americas, LLC

Preclinical

19

Capromorelin

UUniversity of Aarhus

Preclinical

110

Advil

KKenvue Brands

Preclinical

1Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cystic Fibrosis5 trials

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Completed·Vertex Pharmaceuticals·Phase 3·NCT01931839·1,164 enrolled

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Completed·Vertex Pharmaceuticals·Phase 3·NCT01807949·563 enrolled

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Completed·Vertex Pharmaceuticals·Phase 3·NCT01807923·559 enrolled

Show 2 more trials

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Completed·Vertex Pharmaceuticals·Phase 2·NCT01225211·312 enrolled

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Completed·Vertex Pharmaceuticals·Phase 3·NCT01897233·62 enrolled

Phase 12 trials

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Completed·Vertex Pharmaceuticals·Phase 1·NCT01899105·28 enrolled

Phase 1, QT/QTC Interval Study in Healthy Subjects

Completed·Vertex Pharmaceuticals·Phase 1·NCT01910415·200 enrolled

Moderate Hepatic Impairment1 trial

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

Completed·Vertex Pharmaceuticals·Phase 1·NCT01888393·23 enrolled

Lung Disease1 trial

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Completed·Vertex Pharmaceuticals·Phase 3·NCT02390219·46 enrolled

Adult Subject1 trial

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

Completed·Vertex Pharmaceuticals·Phase 1·NCT01768663·80 enrolled

Details

Drug Info

Related News